Checkmate Pharmaceuticals

Checkmate Pharma is a clinical-stage biopharmaceutical company developing a new approach for cancer immunotherapy. The clinical programs are focused on enabling more people with cancer to benefit from the promise of novel immunotherapies. They leveraging their expertise in the field of CpG oligonucleotides to discover and develop immunotherapies designed to increase the efficacy of existing immunotherapies and to provide new treatment options for patients and their healthcare providers. Checkmate Pharmaceutical was founded in 2015 and is headquartered in Cambridge, Massachusetts.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

CAMBRIDGE, Mass., Jan. 03, 2022 (GLOBE NEWSWIRE) -- Checkmate Pharmaceuticals, Inc. (NASDAQ: CMPI) (“Checkmate”), a clinical stage biopharmaceutical company focused on developing its proprietary technology to harness the power of the immune system to combat cancer, today announced that Alan Fuhrman, Interim CEO and President, will present at the H.C. Wainwright BioConnect Virtual Conference being held on January 10-13, 2022. The pre-recorded webcast will be available on-demand starting on Monday, January 10 at 7:00am ET. Checkmate will also host 1x1 investor meetings during the conference.

Checkmate Pharmaceuticals to Present at the H.C. Wainwright BioConnect Virtual Conference

Nilesh Kumar, Ph.D. departs Board of Directors upon transition to new role at Wellington Management Nilesh Kumar, Ph.D. departs Board of Directors upon transition to new role at Wellington Management

Checkmate Pharmaceuticals Strengthens Board of Directors with Appointment of Joy Yan, M.D., Ph.D.

CAMBRIDGE, Mass., Dec. 20, 2021 (GLOBE NEWSWIRE) -- Checkmate Pharmaceuticals, Inc. (NASDAQ: CMPI) (“Checkmate”), a clinical stage biopharmaceutical company focused on developing its proprietary technology to harness the power of the immune system to combat cancer, today announced that patient dosing was initiated in the anti-PD-1 refractory cutaneous squamous cell carcinoma (CSCC) arm of a Phase 2 multi-indication study evaluating the efficacy and safety of vidutolimod in combination with cemiplimab for the treatment of patients with anti-PD-1 refractory CSCC. Vidutolimod is an advanced generation Toll-like receptor 9 (TLR9) agonist, delivered as a biologic virus-like particle utilizing a CpG-A oligodeoxynucleotide as a key component.

Checkmate Pharmaceuticals Announces Initiation of Patient Dosing in Phase 2 Multi-Indication Trial Using Vidutolimod

CAMBRIDGE, Mass., Nov. 15, 2021 (GLOBE NEWSWIRE) -- Checkmate Pharmaceuticals, Inc. (NASDAQ: CMPI) (“Checkmate”), a clinical stage biopharmaceutical company focused on developing its proprietary technology to harness the power of the immune system to combat cancer, today announced that Alan Fuhrman, Interim CEO and President, will present at the Piper Sandler 33rd Annual Virtual Healthcare Conference. The pre-recorded webcast will be available on-demand beginning on Monday, November 22 at 10:00am ET through Thursday, December 2, 2021. Checkmate will also host 1x1 investor meetings during the conference.

Checkmate Pharmaceuticals to Present at the Piper Sandler 33rd Annual Virtual Healthcare Conference

Alan Fuhrman appointed interim President and CEO

Checkmate Pharmaceuticals Announces Third Quarter 2021 Financial Results and Provides Business Update

Vidutolimod in combination with pembrolizumab demonstrated promising clinical activity in patients with PD-1 blockade-refractory melanoma with an ORR of 23.5% per RECIST v1.1

Checkmate Pharmaceuticals Presents Final Clinical Data for Phase 1b Study Evaluating Vidutolimod at The Society for Immunotherapy of Cancer (SITC) 36th Annual Meeting

CAMBRIDGE, Mass., Nov. 11, 2021 (GLOBE NEWSWIRE) -- Checkmate Pharmaceuticals, Inc. (NASDAQ: CMPI) (“Checkmate”), a clinical stage biopharmaceutical company focused on developing its proprietary technology to harness the power of the immune system to combat cancer, today announced that James Wooldridge, MD, Chief Medical Officer, will present virtually at the Jefferies London Healthcare Conference taking place November 16-19, 2021. The pre-recorded webcast will be available on-demand beginning on Thursday, November 18 at 3:00am ET through Friday, November 19 at 12:00pm ET. Checkmate will also host 1x1 investor meetings during the conference.

Checkmate Pharmaceuticals to Present at the Jefferies London Healthcare Conference

CAMBRIDGE, Mass., Nov. 01, 2021 (GLOBE NEWSWIRE) -- Checkmate Pharmaceuticals, Inc.  (NASDAQ: CMPI) (“Checkmate”), a clinical stage biotechnology company focused on developing proprietary technology to harness the power of the immune system to combat cancer, today announced that final clinical data from the Phase 1b study, CMP-001-001, of vidutolimod, an advanced generation Toll-like receptor 9 (TLR9) agonist, in combination with pembrolizumab or as a monotherapy will be presented at The Society for Immunotherapy of Cancer (SITC) 36th Annual Meeting to be held in person and virtually November 10-14, 2021.

Checkmate Pharmaceuticals Announces Final Data Presentation for Phase 1b Study Evaluating Vidutolimod at The Society for Immunotherapy of Cancer (SITC) 36th Annual Meeting

Alan Fuhrman, experienced biotech executive and Checkmate board member, appointed as interim President and CEO Alan Fuhrman, experienced biotech executive and Checkmate board member, appointed as interim President and CEO

Checkmate Pharmaceuticals Announces CEO Transition

Live presentation and Q&A moderated by Jefferies Equity Research on Tuesday, October 26, 2021 at 11:00am ET

Checkmate Pharmaceuticals Announces Webcast on Innate Immune Modulators and Vidutolimod (CMP-001)

Given the early clinical data on Checkmate Pharmaceuticals Inc's (NASDAQ:CMPI) vidutolimod, key opinion leaders remain “positively biased on its outlook,” according to BofA Securities. The Checkmate Pharmaceuticals Analyst: Jason Zemansky upgraded Checkmate Pharmaceuticals from Neutral to Buy and lowered the price target from $19 to $7.

Why BofA Turned Bullish On Checkmate Pharmaceuticals, But Slashed Price Target

CAMBRIDGE, Mass., Sept. 14, 2021 (GLOBE NEWSWIRE) -- Checkmate Pharmaceuticals Inc. (NASDAQ: CMPI) (“Checkmate”), a clinical stage biopharmaceutical company focused on developing its proprietary technology to harness the power of the immune system to combat cancer, today announced that Barry Labinger, CEO, will present at the Cantor Virtual Global Healthcare Conference on Thursday, September 30 from 10:40-11:10am ET. Checkmate will also host 1x1 investor meetings during the conference.

Checkmate Pharmaceuticals to Present at the Cantor Virtual Global Healthcare Conference

Clinical trial programs for vidutolimod (CMP-001) in melanoma and head and neck cancer indications ongoing

Checkmate Pharmaceuticals Announces Second Quarter 2021 Financial Results and Provides Business Update

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Checkmate Pharmaceuticals to Present at the BTIG Virtual Biotechnology Conference

Checkmate Pharmaceuticals to Present at the BTIG Virtual Biotechnology Conference

CAMBRIDGE, Mass., May 20, 2021 (GLOBE NEWSWIRE) -- Checkmate Pharmaceuticals Inc. (NASDAQ: CMPI) (“Checkmate”), a clinical stage biopharmaceutical company focused on developing its proprietary technology to harness the power of the immune system to combat cancer, today announced that Barry Labinger, CEO, will present at the Jefferies Virtual Healthcare Conference from 2:00-2:25pm ET on Tuesday, June 1, 2021. Checkmate will also host 1x1 investor meetings during the conference.

Checkmate Pharmaceuticals to Present at the Jefferies 2021 Virtual Healthcare Conference

CAMBRIDGE, Mass., May 13, 2021 (GLOBE NEWSWIRE) -- Checkmate Pharmaceuticals, Inc. (NASDAQ: CMPI) (“Checkmate”), a clinical stage biopharmaceutical company focused on developing its proprietary technology to harness the power of the immune system to combat cancer, today announced first quarter 2021 financial results and provided an update on recent progress.

Checkmate Pharmaceuticals Reports First Quarter 2021 Financial Results and Provides Update on Recent Progress

CAMBRIDGE, Mass., May 10, 2021 (GLOBE NEWSWIRE) -- Checkmate Pharmaceuticals, Inc. (NASDAQ: CMPI) (“Checkmate”), a clinical stage biopharmaceutical company focused on developing its proprietary technology to harness the power of the immune system to combat cancer, today announced the development program expansion of vidutolimod (CMP-001) into non-melanoma skin cancers in combination with Libtayo® (cemiplimab) under a clinical supply agreement with Regeneron Pharmaceuticals, Inc. (“Regeneron”). Vidutolimod is an advanced generation Toll-like receptor 9 (TLR9) agonist, delivered as a biologic virus-like particle utilizing a CpG-A oligodeoxynucleotide as a key component. Cemiplimab is a PD-1 blocking antibody being jointly developed by Regeneron and Sanofi.

Checkmate Pharmaceuticals Announces Clinical Supply Agreement with Regeneron to Evaluate Vidutolimod (CMP-001) in Combination with Libtayo® (cemiplimab)

CAMBRIDGE, Mass., May 04, 2021 (GLOBE NEWSWIRE) -- Checkmate Pharmaceuticals, Inc. (NASDAQ: CMPI) (“Checkmate”), a clinical stage biopharmaceutical company focused on developing its proprietary technology to harness the power of the immune system to combat cancer, today announced that patient dosing was initiated in a Phase 2 trial intended to assess the efficacy and safety of vidutolimod (CMP-001) in combination with nivolumab for the treatment of patients with anti-PD-1 refractory advanced melanoma. Vidutolimod is an advanced generation Toll-like receptor 9 (TLR9) agonist, delivered as a biologic virus-like particle utilizing a CpG-A oligodeoxynucleotide as a key component. Checkmate previously announced initiation of dosing in patients in an additional trial which is evaluating the efficacy and safety of vidutolimod in combination with nivolumab compared to nivolumab monotherapy in patients with first-line metastatic or unresectable melanoma. The data from these two trials are intended to support a biologics license application for the treatment of patients with anti-PD-1 refractory advanced melanoma.

Checkmate Pharmaceuticals Announces Initiation of Patient Dosing in Potential Registration Trial of Vidutolimod (CMP-001) in Patients with Anti-PD-1 Refractory Advanced Melanoma

CAMBRIDGE, Mass., April 28, 2021 (GLOBE NEWSWIRE) -- Checkmate Pharmaceuticals Inc. (NASDAQ: CMPI) (“Checkmate”), a clinical stage biopharmaceutical company focused on developing its proprietary technology to harness the power of the immune system to combat cancer, today announced that Barry Labinger, CEO, will present at the upcoming Bank of America Securities 2021 Virtual Healthcare Conference at 1:15pm ET on Wednesday, May 12, 2021. Checkmate will also host 1x1 investor meetings during the conference.

Checkmate Pharmaceuticals to Present at the Bank of America Securities 2021 Virtual Healthcare Conference

Checkmate Pharmaceuticals, Inc. is a small clinical-stage biotech focused on the immune-system-based therapeutic development for combating cancer, particularly targeting TLR9 of pDCs with virus-like delivery. Checkmate Pharmaceuticals currently has one therapeutic in their pipeline known as Vidutolimod ("CMP-001"), a CPG-A TLR9 agonist, being tested in multiple clinical trials for various indications including HNSCC and Melanoma.

Checkmate: Promising pDC Therapeutic Holds Triple-Digit Upside In Melanoma

CAMBRIDGE, Mass., April 19, 2021 (GLOBE NEWSWIRE) -- Checkmate Pharmaceuticals Inc. (NASDAQ: CMPI) (“Checkmate”), a clinical stage biopharmaceutical company focused on developing its proprietary technology to harness the power of the immune system to combat cancer, today announced the initiation of dosing in a Phase 2 proof-of-concept trial in patients with head and neck squamous cell carcinoma (HNSCC). The trial will assess the efficacy and safety of vidutolimod (CMP-001) in combination with pembrolizumab for the treatment of patients with first-line relapsed or metastatic HNSCC. The results of this trial are expected in the 2nd half of 2022, with initial data in a subset of patients anticipated before the end of 2021.

Checkmate Pharmaceuticals Announces Initiation of Patient Dosing in Phase 2 Head and Neck Cancer Trial

CAMBRIDGE, Mass., April 11, 2021 (GLOBE NEWSWIRE) -- Checkmate Pharmaceuticals, Inc. (NASDAQ: CMPI) (“Checkmate”), a clinical stage biopharmaceutical company focused on developing its proprietary technology to harness the power of the immune system to combat cancer, today announced the presentation of new translational data from Checkmate's Phase 1b trial of vidutolimod (CMP-001) in combination with pembrolizumab in patients with advanced anti-PD-1 refractory melanoma.

Checkmate Pharmaceuticals Presents New Clinical Trial Translational Data with Vidutolimod at the 2021 American Association for Cancer (AACR) Annual Meeting

Agile Therapeutics

Cyclo Therapeutics, Inc.

Gold Resource

Rhythm Pharmaceuticals

Windtree Therapeutics

William Penn Bancorp

Insider buying could be a bullish sign for a stock. Insiders may sell their shares for many reasons.

7 Beaten Down Stocks with Significant Insider Buying

CAMBRIDGE, Mass., March 29, 2021 (GLOBE NEWSWIRE) -- Checkmate Pharmaceuticals, Inc. (NASDAQ: CMPI) (“Checkmate”), a clinical stage biopharmaceutical company focused on developing its proprietary technology to harness the power of the immune system to combat cancer, today announced full year 2020 financial results and provided an update on recent progress.

Checkmate Pharmaceuticals Reports Full Year 2020 Financial Results and Provides Update on Recent Progress

CAMBRIDGE, Mass., March 10, 2021 (GLOBE NEWSWIRE) -- Checkmate Pharmaceuticals, Inc. (NASDAQ: CMPI) (“Checkmate”), a clinical stage biopharmaceutical company focused on developing its proprietary technology to harness the power of the immune system to combat cancer, today announced that it will present new translational data at the 2021 American Association for Cancer Research (AACR) Annual Meeting taking place virtually from April 10-15, 2021. Data from Checkmate's Phase 1b trial of CMP-001 in subjects with advanced melanoma will be presented in an oral presentation during the Clinical Trials with Novel Immuno-oncology Strategies Session.

News for Checkmate Pharmaceuticals Stock (CMPI)